Inaphaea Deal Extension With Dominion
ValiRx PLC
("ValiRx" or the "Company")
Inaphaea Deal Extension With Dominion
London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following update on the commercial activity of its wholly owned subsidiary Inaphaea BioLabs ("Inaphaea").
Inaphaea is pleased to announce that it has signed an extension to the evaluation and commercial use agreement with UK based Dominion Biotech Ltd ("Dominion") announced on 30 April 2025. Under the extension, Inaphaea will share access to results from a proprietary screen of approximately 3000 FDA approved drugs ("3k Screen") generated in a panel of Patient Derived Cells. The drugs are approved for non-cancer applications and Dominion will mine the data for potential cancer applications, carrying out routine analysis to validate the most promising candidates at its own expense; the parties will agree and share any additional in-depth studies if required. The results of the analysis will be jointly owned and both parties will share equally all costs associated with filing, prosecution and maintenance of any arising patents for any repurposed drugs.
The parties will work together to commercialise any new assets either to the owner of the original drug compounds or alternative companies interested in the repurposed assets. Both companies will be free to pursue further research and development projects based on the findings. All revenues generated from this arrangement shall be equally shared after directly attributable costs.
Mark Eccleston, CEO of ValiRx commented "This is an excellent opportunity to unlock additional value from existing data sets acquired with our biobank. We believe there could be significant untapped potential for drug repurposing within this data set which can be realised at a minimal cost by working with our new partner, Dominion. Whilst ValiRx remains committed to its model of evaluation and in-licensing of novel assets, we will leverage all potential value from our assets, including our extensive data sets, particularly where we can achieve some quick wins from established drugs with validated safety profiles. We are pleased to be able to extend our initial agreement with Dominion and look forward to further opportunities to build value through our collaboration."
Anthony Holmes, CEO of Dominion commented "This collaboration with Inaphaea represents an exciting opportunity to unlock hidden value in existing approved drugs. By analysing Inaphaea's extensive drug screening database against patient-derived cancer models, we aim to identify novel cancer applications for established compounds. This approach could significantly accelerate the development timeline for new cancer treatments, as these drugs have already cleared important safety hurdles. Dominion is committed to applying our analytical expertise to this valuable dataset, potentially creating win-win opportunities for pharmaceutical companies while ultimately providing cancer patients with entirely new treatment options that would otherwise not exist."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
https://valirx.com/link/VyEObr |
|
ValiRx plc
Dr Mark Eccleston, CEO
|
Tel: +44 115 784 0025 Mark.Eccleston@valirx.com
|
|
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti
|
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0) 20 7186 9000 |
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director
|
+44 (0) 115 787 0206
lucy@vformation.biz sue@vformation.biz |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 minute ago Barr (A.G.)
- 8 minutes ago Personal Group Holdings
- 11 minutes ago Grainger
- 40 minutes ago Helios Underwriting
- 1 hour ago SSE